A conversation with Chris Hwang, CTO, Transcenta Holding Ltd.
At a recent Evaluating BioPharma virtual event, moderator John Bonham-Carter asked Chris Hwang, chief technology officer at Transcenta Holding Ltd., about Chris’s journey and experiences with continuous bioprocessing thus far in his career.
The manufacturing lag in developing innovative biological therapeutics has created a bottleneck, so the industry needs better streamlining. That's where establishing a strategic partnership with the right CDMO partner can help to accelerate your development and manufacturing timeline.
Size exclusion chromatography is the go-to analytical method for therapeutic protein drugs. This article describes the factors affecting the reproducibility of columns and how you can minimize column variation.
Explore the three phases of sterile injectable project tech transfer, including how to bridge information gaps and facilitate successful regulatory filing at this fundamental stage of drug development.
Recognizing the prominent role of biosimilar medicines in delivering access to life-changing biological therapies, the ongoing dialogue on cancer and other non-communicable diseases is pointing toward greater value for healthcare systems, enabling progress toward integrated care for patients. Throughout the conference, debate, exchanges, and the presentation of examples and current practices will all foster ideas and data sharing. Join us! Register here!